Key result
Adjuvant and neoadjuvant chemotherapy using anthracycline plus ifosfamide may provide survival benefits for patients with high-risk localized soft tissue sarcomas compared with surgery alone.
Why the study?
Perioperative chemotherapy is a potential treatment option for patients with soft tissue sarcomas at high risk for recurrence or metastasis, but role and efficacy of adjuvant and neoadjuvant regimens warrant discussion.
Does adjuvant or neoadjuvant chemotherapy improve survival in patients with high-risk soft tissue sarcomas compared to surgery alone?
Design
Review
Authors
Loading...
Supports perioperative anthracycline-ifosfamide in high-risk localized STS; strengthens RCT evidence for multimodal therapy.
Does adjuvant or neoadjuvant chemotherapy improve survival in patients with high-risk soft tissue sarcomas compared to surgery alone?
Adjuvant and neoadjuvant chemotherapy, particularly anthracycline plus ifosfamide, may offer survival benefits for patients with high-risk soft tissue sarcomas.
Tanaka et al. (2020) conducted a review in Soft tissue sarcomas. Adjuvant and neoadjuvant chemotherapy vs. Surgery alone was evaluated. Adjuvant and neoadjuvant chemotherapy using anthracycline plus ifosfamide may provide survival benefits for patients with high-risk localized soft tissue sarcomas compared with surgery alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: